Rob Menzies

Dr. Rob Menzies


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Amalie DydaAmalie Dyda
Amalie Dyda
SKSurendra Karki
Surendra Karki
AHAndrew Hayen
Andrew Hayen
RMRaina MacIntyre
Raina MacIntyre
RMRob Menzies
Rob Menzies
BLBette Liu
Bette Liu
In the absence of an adult vaccination register, coverage estimates for influenza and pneumococcal vaccination come from surveys and other data sources. Systematic review and meta-analysis of studies examining vaccination coverage in Australian adults from 1990 to 2015, focusing on groups funded under the National Immunisation Program, and intervals prior to and following the introduction of universal funding. Twenty-two studies met the inclusion criteria; 18 used self-report to determine vaccination status. There were 130 unique estimates of coverage extracted. Among adults aged ≥65y, during the period of universal funding (1999-onwards), the summary estimate of annual influenza vaccination coverage from 27 point estimates was 74.8 % (95 % CI 73.4–76.2 %; range 63.9–82.4 %); prior to this period (1992–1998) from 10 point estimates it was 61.3 % (95 % CI 58.0–64.6 %; range 44.3–71.3 %). For the period of universal funding for pneumococcal vaccination (2005-onwards) the summary estimate for coverage was 56.0 % (95 % CI 53.2–58.8 %; range 51.2–72.8 %, 10 point estimates); prior to 2005 it was 35.4 % (95 % CI 18.8–52.0 %; range 15.4–45.2 %). Coverage for both vaccines was significantly higher following the introduction of universal funding. Influenza vaccination coverage in those aged 18–65 years with a medical indication was lower but data were not combined. Seven studies reported on Aboriginal Australians with three studies reporting five coverage estimates for influenza vaccination in adults ≥65 years (range 71 % - 89 %). Adult influenza and pneumococcal vaccination coverage has increased since the introduction of universal funding, but remains sub-optimal, with pneumococcal coverage lower than influenza. Implications: This review highlights the need for more coverage data overall and in high risk groups, to support public health programs to improve coverage.

21 October 2016 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
SJSanjay Jayasinghe
Sanjay Jayasinghe
RMRob Menzies
Rob Menzies
CCClayton Chiu
Clayton Chiu
CTCindy Toms
Cindy Toms
CBChristopher Charles Blyth
Christopher Charles Blyth
PMPeter McIntyre
Peter McIntyre
Background Australia introduced universal PCV7 from 2005, replaced by PCV13 in 2011; uniquely among high-income countries giving doses at 2,4 &6 months (3+0schedule). Data on impact of a timely 3+0 PCV schedule with high coverage are sparse, with none for PCV13. Methods We used national surveillance of invasive pneumococcal disease (IPD) from 2002 for baseline and appropriate later comparison periods to calculate incidence rate ratios (IRRs) by serotype and age using a Poisson model. PCV coverage was assessed from the Australian Childhood Immunisation Register. Results After 9 years of timely 3 dose PCV coverage of >92%, all-age IPD in Australia almost halved (IRR 0.53; 95%CI 0.50-0.57), but differed by PCV era. Reductions in IPD due to vaccine serotypes from PCV7 (IRR 0.20; 0.17-0.22) were about two-fold greater than for IPD due to extra serotypes in PCV13 (13v-non7v) in a similar period (IRR 0.58;CI 0.51-0.66). Post-PCV13 declines in serotype 19A IPD in persons aged <2 years (IRR 0.23; 0.13-0.35) and ≥2 years (IRR 0.35; 0.28-0.44) differed from other 13v-non7v IPD (<2 years IRR 0.73; 0.35-1.48 and ≥2 years IRR 0.96; 0.81-1.15). Meningitis due to vaccine serotypes nearly disappeared in children eligible for three PCV13 doses. IPD due to non-PCV13 serotypes increased by 30% compared to 76% for non-PCV7 serotypes in equivalent period of vaccine use. Conclusions Reductions in vaccine type IPD post-PCV13 were inferior to Australian experience with PCV7 and reports from high-income countries giving a PCV booster dose. Applicability of findings to other settings would depend on age of IPD onset, serotype profile and timeliness of vaccination.

15 January 2006 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MWM. Watson
M. Watson
RGR. Gilmour
R. Gilmour
RMRob Menzies
Rob Menzies
MFM. Ferson
M. Ferson
PMPeter McIntyre
Peter McIntyre
NNNew South Wales Pneumococcal Network
New South Wales Pneumococcal Network
Background. Increases in incidence of invasive pneumococcal disease (IPD) during the colder months of the year in temperate regions are well recogniz

1 October 1993 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
ELE.R. Lumbers
E.R. Lumbers
JBJ.H. Burrell
J.H. Burrell
RMRob Menzies
Rob Menzies
ASA.D. Stevens
A.D. Stevens
Renal function was studied in chronically catheterized fetal sheep (119–128 days gestation), before and during treatment of the ewe with the angiotensin converting enzyme (ACE) inhibitor, Captopril, which crosses the placenta and blocks the fetal renin angiotensin system. An i.v. dose of 15 mg (about 319 μg kg−1) of Captopril to salt‐replete ewes followed by an infusion to the ewe of 6 mg h−1 (about 128 μg kg−1 h−1) caused a fall in fetal arterial pressure (P < 0.01), and a rise in fetal renal blood flow (RBF) from 67.9 ± 5.6 to 84.9 ± 8.3 ml min−1 (mean ± s.e.mean) (P < 0.05). Renal vascular resistance and glomerular filtration rate (GFR) fell (P < 0.01); fetal urine flow (P < 0.01) and sodium excretion declined (P < 0.05). Ewes were treated for the next 2 days with 15 mg Captopril twice daily. On the 4th day, 15 mg was given to the ewe and fetal renal function studied for 2 h during the infusion of Captopril (6 mg h−1) to the ewe. Of the 9 surviving fetuses, 3 were anuric and 3 had low urine flow rates. When 6 μg kg−1 h−1 of angiotensin II was infused directly into the fetus RBF fell from 69 ± 10.1 ml min−1 to 31 ± 13.9 ml min−1, GFR rose (P < 0.05) and urine flow (P < 0.01) and sodium excretion increased in all fetuses. It is concluded that the small fall in fetal arterial pressure partly contributed to the fall in fetal GFR but in addition, efferent arteriolar tone fell so that the filtration pressure fell further. Thus maintenance of fetal renal function depends on the integrity of the fetal renin angiotensin system. These findings explain why use of ACE inhibitors in human pregnancy is associated with neonatal anuria.

17 February 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
SJSanjay Jayasinghe
Sanjay Jayasinghe
CCClayton Chiu
Clayton Chiu
HQHelen Quinn
Helen Quinn
RMRob Menzies
Rob Menzies
RGRobin Gilmour
Robin Gilmour
PMPeter McIntyre
Peter McIntyre
Unique among high-income countries, Australia has used a 3 + 0 schedule (3 primary doses, no booster) for infant pneumococcal conjugate vaccine (PCV) since January 2005, initially 7 valent (PCV7) then 13 valent (PCV13) from July 2011. We measured vaccine effectiveness (VE) of both PCVs against invasive pneumococcal disease (IPD) using 2 methods. Cases were IPD notifications to the national surveillance system of children eligible for respective PCVs. For case-control method, up to 10 age-matched controls were derived from the Australian Childhood Immunisation Register. For indirect cohort method, controls were IPD cases due to serotypes not in PCVs. VE was calculated as (1 - odds ratio [OR]) × 100 by logistic regression. VE waning was estimated as odds of vaccine type (VT) IPD in consecutive 12-month periods post-dose 3. Between 2005 and 2014, there were 1209 and 308 IPD cases in PCV7-eligible and PCV13-eligible cohorts, respectively. Both methods gave comparable VE estimates. In infants, VE for 3 doses against VT IPD was 92.9% (95% confidence interval [CI], 27.7% to 99.3%) for PCV7 and 86.5% (95% CI, 11.7% to 97.9%) for PCV13. From 12 months post-dose 3, the odds of VT IPD by 24-36 months increased significantly for PCV7 (5.6, 95% CI, 1.2-25.4) and PCV13 (5.9, 95% CI, 1.0-35.2). For both PCVs in a 3 + 0 schedule, despite similar VE, progressive increase in breakthrough cases only occurred post-PCV13. This supports the importance of a booster dose of PCV13 in the second year of life to maintain protection.